Syncona Limited

Freeline to present further FLT180a data at EAHAD

RNS Number : 4743A
Syncona Limited
21 January 2020
 

 

Freeline to present further FLT180a data at EAHAD

21 January 2020

Syncona announces that its portfolio company, Freeline will be disclosing further data from its Phase 1/2 B-AMAZE trial investigating a novel gene therapy, FLT180a, for Haemophilia B on Friday 7 February 2020 at 14:00-15:00 at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), The Hague, Netherlands. Syncona will provide the details of this data via an RNS announcement. Previously, Freeline has disclosed 66- and 74-week data for the first cohort of two patients who were treated with the lowest study dose (4.5x1011vg/kg).

The Hot Topics session details have been published today and are available on the EAHAD website at https://eahadcongress.com/programme/programme/#friday.

Title: Phase 1/2 interim data from B-AMAZE study of adeno associated virus (AAV) gene therapy (FLT180a) confirms progress towards achieving Factor IX levels in the normal range for patients with severe or moderately severe haemophilia B

Presenter: Dr Pratima Chowdary

Session Date and Time:  Friday 7 February 2020 at 14:00 - 15:00 pm CET

 

[ENDS]

Enquiries

Syncona Ltd

Siobhan Weaver / Annabel Clay  

Tel: +44 (0) 20 3981 7940

 

FTI Consulting

Ben Atwell / Natalie Garland-Collins

Tel: +44 (0) 20 3727 1000

Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com  

Forward-looking statements - this announcement contains certain forward-looking statements with respect to the portfolio of investments of Syncona Limited. These statements and forecasts involve risk and uncertainty because they relate to events and depend upon circumstances that may or may not occur in the future. There are a number of factors that could cause actual results or developments to differ materially from those expressed or implied by these forward-looking statements. In particular, many companies in the Syncona Limited portfolio are conducting scientific research and clinical trials where the outcome is inherently uncertain and there is significant risk of negative results or adverse events arising. In addition, many companies in the Syncona Limited portfolio have yet to commercialise a product and their ability to do so may be affected by operational, commercial and other risks.

About Syncona

Syncona is a leading FTSE250 healthcare company focused on founding, building and funding a portfolio of global leaders in life science. Our vision is to build a sustainable, diverse portfolio of 15 - 20 companies focused on delivering transformational treatments to patients in truly innovative areas of healthcare, through which we are seeking to deliver strong risk-adjusted returns for shareholders.

We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses. We take a long-term view, underpinned by a strategic capital base which provides us with control and flexibility over the management of our portfolio. We focus on delivering dramatic efficacy for patients in areas of high unmet need.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRAFLFELLTILFII